Close
Slide 1

PUBLICATIONS

OPRI has been leading the paradigm shift in real world evidence for the past 12 years, by delivering pragmatic clinical trials, disease registries and database research.
OPRI’s founder, Professor David Price, has been a pioneer in setting new quality standards for database research which are fully adhered to by the research institute.

HOME PAGE
2020 pub
Publications
HOME
2020 PUBLICATIONS
2019 PUBLICATIONS
2020 ACCEPTED ABSTRACTS

2020 Publications COPD

Advancing the Patient Experience (APEX) in COPD registry: Study design and strengths - Accpeted in Journal of the American Board of Family Medicine

Blood Eosinophil Count Predicts Treatment Failure and Hospital Readmission for COPD - Accepted in ERJ Open Research

Development of the Advancing the Patient EXperience (APEX) in COPD registry: a modified Delphi Study - Accepted in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation

2020 pub
Publications
HOME
2020 PUBLICATIONS
2019 PUBLICATIONS
2020 ACCEPTED ABSTRACTS

2020 Publications | Severe Asthma

Potential severe asthma hidden in UK primary care - JACI In Pract (Severe Asthma)

Biomarkers
Other Studies

Evaluating the Real-life Effect of MP-AzeFlu On Asthma Outcomes In Patients With Allergic Rhinitis and Asthma In UK Primary Care - WAO J

2019 pub
Publications
HOME
2020 PUBLICATIONS
2019 PUBLICATIONS
2020 ACCEPTED ABSTRACTS

2019 Publications

Severe Asthma
COPD
Other Studies
2020 abstracts
Publications
HOME
2020 PUBLICATIONS
2019 PUBLICATIONS
2020 ACCEPTED ABSTRACTS

AAAAI 2020 Annual Meeting

Asthma-Related Outcomes in A Real-World Study of MP-AzeFlu to Treat Allergic Rhinitis
Evaluating the Real-life Effect of MP-AzeFlu On Asthma Control In Patients With Allergic Rhinitis and Asthma In UK Primary Care

REG 2020

Cluster analysis according to biomarker profile differentiates clinical subgroups in the International Severe Asthma Registry (ISAR)

The Demographic and Clinical Characteristics of Eosinophilic and non-Eosinophilic Phenotypes of Severe Asthma in International Severe Asthma Registry (ISAR)
Demographic and Clinical Characteristics of Patients with Severe Asthma who Continued, Stopped or Switched Biologic Therapy

COPD Primary Care: Providing a Clinically Relevant Picture for Clinicians

2020 abstracts
Publications
HOME
2020 PUBLICATIONS
2019 PUBLICATIONS
2020 ACCEPTED ABSTRACTS

ATS 2020

The Impact of Exacerbation Burden on Lung Function Trajectory in a Broad UK Asthma Population: A Large Longitudinal Cohort Study

Global Access for Biologics in the Treatment of Severe Asthma: A Challenge to Personalized Medicine

Biologic Utilization Patterns: Data from the International Severe Asthma Registry (ISAR)

A Global Survey of Blood Eosinophil Distribution in Severe Asthma Patients: Data from the International Severe Asthma Registry (ISAR)

Characterization of Eosinophilic and Non-Eosinophilic Severe Asthma Phenotypes and Proportion of Patients with These Phenotypes in the International Severe Asthma Registry (ISAR)

Biomarker Relatability in the International Severe Asthma Registry

Disease Burden for Patients with Chronic Obstructive Pulmonary Disease Receiving Maintenance Therapy

Exit full screenEnter Full screen
previous arrow
next arrow